TELA

TELA Bio Inc

Add to Watchlist

Advanced Chart

1.780

-0.02(-1.111%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.850

Open

1.800

VWAP

1.76

Vol

54.74K

Mkt Cap

70.52M

Low

1.730

Amount

96.24K

EV/EBITDA(TTM)

Total Shares

24.66M

77.72M

EV/OCF(TTM)

P/S(TTM)

0.93

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

23.03M

+24.37%

-0.163

-34.67%

24.94M

+41.29%

-0.162

-29.57%

21.78M

+14.9%

-0.200

-52.38%

Estimates Revision

The market is revising Downward the revenue expectations for TELA Bio, Inc. (TELA) for FY2025, with the revenue forecasts being adjusted by -0.73% over the past three months. During the same period, the stock price has changed by 30.88%.

Revenue Estimates for FY2025

Revise Downward

-0.73%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.93%

In Past 3 Month

Stock Price

Go Up

+30.88%

In Past 3 Month

4 Analyst Rating

132.02% Upside

Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 4.13 USD with a low forecast of 1.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

132.02% Upside

Current: 1.780

Low

1.50

Averages

4.13

High

7.00

132.02% Upside

Current: 1.780

Low

1.50

Averages

4.13

High

7.00

Canaccord Genuity

Caitlin Cronin

Strong Buy

Maintains

$12 → $7

2025-03-21

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$12 → $7

2025-03-21

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Tela Bio to $7 from $12 and keeps a Buy rating on the shares. The firm said they posted a tough quarter significantly below consensus revenues as it lost a number of sales reps to competitors in the Q4 with the sales org already lean post commercial streamlining in the Q3. While the Q4 was a challenging one, the management team are experienced MedTech operators, and Canaccord believes they would need to see sustained sales org churn before becoming materially less constructive.

Piper Sandler

Matt O'Brien

Buy

Hold

Downgrades

$5 → $2

2025-03-21

Reason

Piper Sandler

Matt O'Brien

Price Target

$5 → $2

2025-03-21

Downgrades

Buy

Hold

Reason

Citizens Capital Markets

David Turkaly

Buy

Maintains

$12 → $7

2025-03-21

Reason

Citizens Capital Markets

David Turkaly

Price Target

$12 → $7

2025-03-21

Maintains

Buy

Reason

Citizens JMP lowered the firm's price target on Tela Bio to $7 from $12 and keeps an Outperform rating on the shares. Sales in the quarter were impacted by several factors, including competitive rep poaching by smaller wound care companies offering significant comp benefits including guaranteed contracts, the analyst tells investors in a research note. The firm still believes that Tela's two main biologic product platforms provide significant benefits to all constituents and that the premium growth profile here should be sustainable.

Piper Sandler

Matt O'Brien

Buy

Maintains

$8 → $5

2024-11-08

Reason

Piper Sandler

Matt O'Brien

Price Target

$8 → $5

2024-11-08

Maintains

Buy

Reason

Canaccord Genuity

Caitlin Cronin

Strong Buy

Maintains

$12

2024-10-04

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$12

2024-10-04

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for TELA Bio Inc (TELA.O) is -2.69, compared to its 5-year average forward P/E of -4.78. For a more detailed relative valuation and DCF analysis to assess TELA Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.78

Current PE

-2.69

Overvalued PE

-2.92

Undervalued PE

-6.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.81

Current EV/EBITDA

-3.75

Overvalued EV/EBITDA

-3.53

Undervalued EV/EBITDA

-8.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.40

Current PS

0.75

Overvalued PS

5.62

Undervalued PS

1.18

Financials

Annual

Quarterly

FY2025Q2

YoY :

+25.52%

20.20M

Total Revenue

FY2025Q2

YoY :

-21.51%

-9.08M

Operating Profit

FY2025Q2

YoY :

-21.25%

-9.92M

Net Income after Tax

FY2025Q2

YoY :

-56.86%

-0.22

EPS - Diluted

FY2025Q2

YoY :

-27.07%

-8.02M

Free Cash Flow

FY2025Q2

YoY :

+1.50%

69.84

Gross Profit Margin - %

FY2025Q2

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q2

YoY :

-37.25%

-49.13

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

410.0K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

500.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

410.0K

USD

Months

TELA News & Events

Events Timeline

2025-08-11 (ET)

2025-08-11

16:28:14

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

2025-08-11

16:27:34

Tela Bio reports Q2 EPS (22c), consensus (19c)

2025-06-03 (ET)

2025-06-03

16:47:07

Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix

News

5.0

06-03Newsfilter

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

5.0

06-02Newsfilter

TELA Bio Appoints Jeffrey Blizard as President

1.0

05-22Newsfilter

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

People Also Watch

Bragg Gaming Group Inc

Milestone Pharmaceuticals Inc

FAQ

What is TELA Bio Inc (TELA) stock price today?

The current price of TELA is 1.78 USD — it has decreased -1.11 % in the last trading day.

TELA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TELA News & Events

Events Timeline

News

People Also Watch

FAQ

What is TELA Bio Inc (TELA) stock price today?

What is TELA Bio Inc (TELA)'s business?

What is the price predicton of TELA Stock?

What is TELA Bio Inc (TELA)'s revenue for the last quarter?

What is TELA Bio Inc (TELA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for TELA Bio Inc (TELA)'s fundamentals?

How many employees does TELA Bio Inc (TELA). have?

What is TELA Bio Inc (TELA) market cap?